|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Ciba-Geigy
gptkb:Searle_Pharmaceuticals
|
|
gptkbp:activities
|
gptkb:drug
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:1993
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:brand
|
gptkb:Effexor
gptkb:Effexor_XR
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
uncontrolled hypertension
severe renal impairment
hypersensitivity to venlafaxine
|
|
gptkbp:developed_by
|
gptkb:Wyeth_Pharmaceuticals
|
|
gptkbp:dosage_form
|
75 mg to 225 mg daily
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Venlafaxine
|
|
gptkbp:ingredients
|
C17 H19 N O2
|
|
gptkbp:interacts_with
|
gptkb:beer
MAO inhibitors
other antidepressants
|
|
gptkbp:is_atype_of
|
N06 A X16
|
|
gptkbp:is_available_on
|
gptkb:tablet
extended-release capsule
|
|
gptkbp:is_used_for
|
anxiety disorders
major depressive disorder
panic disorder
|
|
gptkbp:legal_issue
|
prescription only
|
|
gptkbp:lifespan
|
5 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:Pfizer
|
|
gptkbp:metabolism
|
gptkb:desvenlafaxine
liver
|
|
gptkbp:side_effect
|
dizziness
nausea
insomnia
dry mouth
increased blood pressure
|
|
gptkbp:symptoms
|
dizziness
fatigue
headache
nausea
irritability
|
|
gptkbp:type_of
|
93413-69-5
|